On February 25, 2025, Roivant Sciences Ltd. announced a significant change in the leadership of Arbutus Biopharma Corporation. The entire Board of Directors of Arbutus resigned and was subsequently replaced. This move was initiated by Roivant's Chief Executive Officer, Matthew Gline.
Roivant beneficially owns and controls 38,847,462 common shares of Arbutus, representing a 20.5% stake in the company. This substantial ownership position allowed Roivant to request and facilitate the board changes. The strategic realignment of Arbutus's board could impact its future direction and collaboration with Genevant Sciences, a Roivant subsidiary.
This event underscores Roivant's active role in managing its investments and leveraging its influence to align strategic objectives. The relationship with Arbutus is particularly relevant due to their joint LNP patent litigation against Moderna and Pfizer/BioNTech, making board control a key factor in pursuing these high-stakes legal actions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.